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research project as clinical data, imaging features and 
quality of life evaluation.  
Conclusions: The creation of a formal ontology is the starting 
point to share and collect data from multiple datasets. It 
allows to obtain a clear and a common interpretation of 
concepts, to report information in standardized large 
database. Along these lines the multi-professional team has 
in use a suitable support to implement decision support 
system based on predictive models.  
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Purpose/Objective: To determine patterns of failure (POF) 
and survival outcomes in newly-diagnosed glioblastoma (ND-
GBM) patients treated on prospective phase I and II clinical 
trials using standard chemoradiotherapy in combination with 
novel chemotherapy. 
Materials and Methods: POF of 77 patients with ND-GBM 
enrolled in prospective clinical trials were reviewed. Patients 
received the current standard of care, including surgical 
debulking, conformal radiation therapy (RT), and 
temozolomide, as well as an investigational chemotherapy 
agent (everolimus, erlotinib, or vorinostat). Patients received 
follow-up MR imaging per protocol at 2-month intervals 
following treatment to evaluate response. Contrast 
enhancement (CE) from T1-weighted post-contrast MRI scans 
was used to define each recurrence volume at the time of 
progression (RecVolp). Additionally, the first suspicious scan 
containing new or increased CE was used to define the initial 
recurrence volume (RecVoli). MRI scans were registered to 
the RT planning CT and dose volume histograms were 
calculated for each RecVol. POF at the time of progression 
(POFp) and initial indication (POFi) were characterized by the 
percent volume encompassed within the 95% dose region as 
central (V95% ≥ 95%) or non-central (V95% < 95%). Here, POFp 
and POFi of each patient were categorized as central only, 
non-central only, or both central and non-central. 
Results: Of the collective patient cohort, POF appeared to 
become increasingly non-central and multifocal with time. 
Recurrence with a non-central component increased from 
14% to 27% (p = 0.07) and multifocal recurrence increased 
from 6% to 16% (p = 0.12) from the time of initial indication 
to progression, respectively. POF depended on the novel 
chemotherapy agent given. POFi were (94% central, 6% non-
central, 0% both) for erlotinib, (79%, 0%, 21%) for everolimus, 
and (77%, 18%, 5%) for vorinostat patient cohorts. Patients 
with unmethylated MGMT promoter had a higher percentage 
of multifocal recurrence (40%) compared to those with 
methylated MGMT promoter (0%) at the time of progression 
(p = 0.01). The overall median PFSi, PFSp, and OS were 4.5, 
8.6, and 17.4 months, respectively. Survival outcomes based 
on the novel chemotherapy agent given were not significantly 
different. 
Conclusions: POF for this ND-GBM cohort treated with novel 
chemotherapy agents were predominantly central, but were 
influenced by the time point of analysis. POF of the overall 
cohort were increasingly non-central at progression as 
compared with initial progression, suggesting that recurrence 
originates from the central region. POF differed between 
novel agents despite similar survival outcomes. Robust and 
properly-timed dosimetric POF analysis may be helpful to 
evaluate biologic aspects of novel therapeutic agents.  
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Purpose/Objective: To compare two schedules of 
hypofractionated radiochemotherapy in naive unresectable 
GBM in terms of toxicity, response and survival: the first one 
was followed by low dose radiation therapy (Hypo-RT-
CT+LDRT), in the second schedule no low dose radiation 
therapy was administered (Hypo-RT-CT). 
Materials and Methods: Patients (KPS > 70, age >18 years) 
underwent biopsy or with gross residual tumor after surgery 
were enrolled in these two studies. In the first study (Hypo-
RT-CT), patients received hypofractionated radiotherapy (35 
Gy in ten fractions) combined with Temozolomide (75 mg/mq 
from the start to the end of RT); in the second study (Hypo-
RT-CT+LDRT) patients received hypofractionated 
radiotherapy (30Gy in ten fractions) with concomitant 
Temozolomide. In both studies adjuvant Temozolomide 
(Stupp like) was administered but it was combined with low 
dose radiation therapy (40 cGy twice on day for 5 days) only 
in Hypo-RT-CT+LDRT study. In all cases clinical target volume 
(CTV) was ring enhancement with residual tumor plus 3 cm. 
Acute and late toxicities were evaluated according to 
Common Terminology Criteria for Adverse Events version 4.0. 
MRI was used in order to evaluate the response to the 
treatment, according to RECIST Guidelines. Moreover overall 
survival (OS) and progression-free survival (PFS) were 
calculated by the Kaplan-Mayer method. 
Results: Forty-two patients (M/F: 25/17) were enrolled from 
June 2010 to May 2014. Twenty-two out of 42 patients were 
enrolled in Hypo-RT-CT while 20 pts in Hypo-RT-CT+LDRT 
study. Most of them (57%) was submitted only to a biopsy 
(Table 1). Two out of 22 patients (9%) of Hypo-RT-CT study 
presented acute toxicities G2 (seizure and headache); in 
Hypo-RT-CT+LDRT we recorded G2 acute toxicities in 4 
patients (10%): 2 thrombocytopenia and 2 leucopenia; G3 
acute toxicity was observed only in one patient. After 
hypofractionated radiochemotherapy, partial response (PR) 
and stable disease (SD) were of 22% and 40% respectively in 
Hypo-RT-CT study, 9% and 14% in Hypo-RT-CT+LDRT. Median 
follow-up was of 24 months (range 6 - 53). Median OS and 1-
yrs survival were of 15 months and 75% respectively for Hypo-
